中国海外宏洋集团(00081.HK)7月合约销售额达60.25亿港元同比增50.47%
格隆汇8月6日丨中国海外宏洋集团(00081.HK)公布,在2019年7月份,中海宏洋系列公司实现合约销售额60.25亿港元,同比增长50.47%,合约销售面积39.86万平方米。
在2019年1至7月份,累计合约销售额346.51亿港元,同比增长6.76%,合约销售面积277.27万平方米。截至2019年7月底,累计认购未签约额11.14亿港元及认购未签约面积7.34万平方米。
在2019年7月份集团於广东省清远市和江苏省南通市新增项目4个,总权益发展面积59.55万平方米,需支付地价人民币44.71亿元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.